Gabriela Burgos: My key takeaways from ASCO 2024
Gabriela Burgos, Associate Research Director- Evidence Generation Lead, RWE at Oracleย shared a post on LinkedIn:
โAbsolutely invigorated by American Society of Clinical Oncology (ASCO) 2024! Lots of information was shared and insightful client meetings were held.
Here are some key takeaways from my time there:
๐๐๐ฃ๐จ๐ซ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ๐ฌ:
โข Phase 2/3 Research: Significant progress in various tumors particularly lung and breast cancer, with biomarker-driven therapies leading the way.
โข Cancer Vaccines: Promising future, especially when combined with immunotherapy (IO). Exciting examples include mRNA vaccine with Pembrolizumab for melanoma and neoantigen vaccine with IO for Lynch Syndrome.
๐๐ ๐ข๐ง ๐๐ง๐๐จ๐ฅ๐จ๐ ๐ฒ:
โข AI’s presence is stronger than ever, with applications ranging from identifying patients in Electronic Medical Records (EMRs) and providing medical recommendations to assisting with note writing and administrative tasks. A standout example is MyEleanor, an AI-based virtual patient navigator, which increased patient’s adherence to colorectal screenings in the Bronx, New York. While AI is transformative, continuous quality checks of both inputs and outputs remain crucial.
๐โ๐๐๐ ๐กโ๐ ๐๐๐ก๐๐ ๐ก ๐๐๐ ๐๐๐๐๐ก๐๐ ๐ก ๐๐๐ฃ๐๐๐๐๐๐๐๐ก๐ , ๐ก๐๐โ, ๐๐๐ ๐๐๐ก๐ ๐ค๐๐ ๐ โ๐๐โ๐๐๐โ๐ก ๐๐ ๐ด๐๐ถ๐, ๐๐๐ ๐๐๐๐๐๐๐’๐ ๐๐๐๐๐ ๐ค๐๐ ๐๐๐๐๐๐ ๐๐๐ ๐๐ ๐๐๐ก๐๐๐๐ ๐ก ๐ก๐ ๐๐ก๐ก๐๐๐๐๐๐ .
๐๐ ๐๐ซ๐๐๐ญ๐ฆ๐๐ง๐ญ ๐๐ซ๐๐๐๐ซ๐๐ง๐๐๐ฌ ๐ข๐ง ๐๐๐ฏ๐๐ง๐๐๐ ๐๐๐ฅ๐๐ง๐จ๐ฆ๐:
โข In collaboration with Bristol Myers Squibb, our study on 1L treatment preferences in advanced melanoma garnered significant interest. Attendees wanted to know the preferences of patients with advanced melanoma and treating oncologists in the current treatment guidelines landscape. Using a discrete choice experiment, findings showed that both patients and oncologists prioritize effective IO regimens while ensuring favorable risk-benefit profiles.
๐๐๐ง๐๐๐ซ ๐๐ฎ๐ซ๐ฏ๐ข๐ฏ๐จ๐ซ๐ฌ๐ก๐ข๐ฉ:
โข I attended a community in practice meeting on cancer survivorship. While the panel topic was developing survivorship programs in institutions, the Q&A discussion was enriched by diverse perspectives from oncologists, program directors, cancer survivors, researchers, and patient advocates. The main points that stood out were that survivorship care needs to align with cancer survivors needs and expectations. As we see in our research at Oracle Life Sciences, the patient experience and voice is crucial in survivorship care.ย Also, survivorship care is in the spotlight, not only on a government and institution scale, but also in research. Given the new treatments available such as IO, there is a gap in understanding cancer survivors outcomes longitudinally.
Feeling inspired by the innovations and the commitment to enhancing patient care. Looking forward to the future of oncology!โ
Source: Gabriela Burgos/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023